Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Life Expectancy With HIV Increases Dramatically
New Hope for HIV Eradication
New Synthetic Proteins Block HIV
Additional Funding Awarded for Adherence Breathalyzer
A New Avenue Opens for Treating KS, CMV and Other Herpes Diseases
New Life for Treatment Interruptions?
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

June 3, 2009

Tesamorelin for Lipodystrophy Approval Application Filed

Montreal-based Theratechnologies announced on Monday, June 1, that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for tesamorelin, its experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy. If approved, tesamorelin will be sold in the United States by EMD Serono.

Tesamorelin is a synthetic human growth hormone–releasing factor. Phase III clinical trials of the drug indicate that it decreases visceral adipose tissue (VAT)—fat deep within the belly—by about 15 percent. Unlike Serostim (recombinant human growth hormone), an earlier contender for treating excess VAT, tesamorelin has fewer side effects when used for at least a year, including a minimal effect on blood sugar (glucose) levels.

“We plan to work closely with the FDA in order to facilitate the completion of their review,” said Martine Ortega, the vice president of compliance and regulatory affairs at Theratechnologies, in a press release issued by the company. “Treatment for excess abdominal fat in HIV patients with lipodystrophy represents an unmet medical need. If approved, tesamorelin could be the first product available to treat this condition,” she noted.

The FDA may take up to 12 months from the date of the NDA submission to decide whether to approve the drug.

Search: tesamorelin, growth hormone, lipodystrophy, lipohypertrophy, VAT, fat, Theratechnologies, Serono


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 3 (of 3 total)    

JED, Toronto, 2009-08-02 21:26:06
A great step, but unless it is available to all people regardless of financial or insurance situations equally, it would become an elitist option for the wealthy and priviledge and not for all on a compassionate grounds if proven not to be affordable - much like Serostim has been for many years now.

Clark, Winston-Salem, 2009-06-14 12:38:22
With being poz for over 20 years now & suffering from Lipo' for the past 10-12 years (rarely go out due to how I look, like "Quasimodo") I know that liposuction usually does not work for long. I just want to look "normal" again! I'd love to be a "lab rat" for this study here in the states...

friend, ct, 2009-06-04 11:11:15
I wonder if this will be covered by insurance?

comments 1 - 3 (of 3 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy